Skip to main content
OpenTrials
Completed

NCT Number: NCT02144220

Remote Access to Care, Everywhere, for Parkinson Disease

The primary objective of this study is to evaluate the feasibility, efficacy and the value of providing care to individuals with Parkinson disease directly into their homes. The specific aims are:

1. To demonstrate the feasibility of conducting remote evaluations of patients with Parkinson disease nationally; 2. To measure the impact of remote care on each patient's ability to improve his or her quality of life (QoL) and better manage his or her Parkinson disease; and 3. To assess the long-term acceptability to patients in receiving ongoing care remotely via telemedicine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–120 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California San Francisco/San Francisco VA Medical Center, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than 30
  • Self reported diagnosis of idiopathic Parkinson disease
  • Ability to converse in English
  • Ability and willingness to provide informed consent and complete study requirements
  • Access to a non-public computer or similar devices with broadband internet.
  • Located in New York, Maryland, Delaware, California, or Florida at time of virtual visit (or veterans with Parkinson disease anywhere in the U.S.)

Exclusion criteria

  • Any condition (e.g.prominent psychosis) that in the investigator's or coordinator's judgment would preclude participation.
  • Concurrent enrollment in another telemedicine study.

Treatment and study plan

Virtual care visit

Other

Video-conferencing visit with a Parkinson disease specialist

Other names: Telemedicine visit, Virtual house call

Primary outcomes

  1. Feasibility

    Time frame: 6 months

    The percent of telemedicine visits completed as scheduled. (Goal >80%)

  2. Change in Quality of Life as Measured by the PDQ-39 Assessment Tool

    Time frame: Baseline and 6 months

    The impact on Quality of life (QoL) as measured by the change in PDQ-39 score from baseline to 6 months. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month. 5-point ordinal scoring system: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better quality of life.

Secondary outcomes

  1. Acceptability

    Time frame: 6 months

    • The percent of patients participated who stated that they are interested in receiving ongoing care for their PD via telemedicine. (Goal >80%)
  2. Feasibility (Descriptive)

    Time frame: 6 months

    Percentage of physician visits where the physician was were satisfied or very satisfied with the virtual visit overall.

  3. Percentage of Patients Who Felt That the Recommendations Improved Their Health

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • Davis Phinney Foundation

Registry information

Official study title

Remote Access to Care, Everywhere: Using Telemedicine to Deliver Patient-centered Care to Patients With Parkinson Disease

Acronym: RACE-PD

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 21, 2014
Registry last updated
Feb 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.